Oricell Therapeutics is a biotechnology company focused on cancer immunotherapy, developing innovative cell therapies and antibody platforms. It operates with a global development approach, leveraging proprietary technologies to advance therapies for solid and hematologic malignancies, with activities centered in China and international collaborations. The company highlights its OriAb and OriCAR platforms, CAR-T programs such as OriCAR-017 and Ori-C101, and CMC capabilities to support clinical development and manufacturing. Its pipeline targets unmet clinical needs in cancers like multiple myeloma, liver cancer, and other solid tumors.
No recent deals for this company.